Tristan Courau

Tristan Courau

Auto-generated profile, based on publicly available information

Tristan Courau

Department of Pathology, University of California, San Francisco, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
TCTristan Courau
Tristan Courau
JBJulie Bonnereau
Julie Bonnereau
JCJustine Chicoteau
Justine Chicoteau
HBHugo Bottois
Hugo Bottois
RRRomain Remark
Romain Remark
LBLionel Le Bourhis
Lionel Le Bourhis
Background Immunotherapies still fail to benefit colorectal cancer (CRC) patients. Relevant functional assays aimed at studying these failures and the efficacy of cancer immunotherapy in human are scarce. 3D tumor cultures, called tumor organoids or spheroids, represent interesting models to study cancer treatments and could help to challenge these issues. Methods We analyzed heterotypic cocultures of human colon tumor-derived spheroids with immune cells to assess the infiltration, activation and function of T and NK cells toward human colorectal tumors in vitro. Results We showed that allogeneic T and NK cells rapidly infiltrated cell line-derived spheroids, inducing immune-mediated tumor cell apoptosis and spheroid destruction. NKG2D, a key activator of cytotoxic responses, was engaged on infiltrating cells. We thus assessed the therapeutic potential of an antibody targeting the specific ligands of NKG2D, MICA and MICB, in this system. Anti-MICA/B enhanced immune-dependent destruction of tumor spheroid by driving an increased NK cells infiltration and activation. Interestingly, tumor cells reacted to immune infiltration by upregulating HLA-E, ligand of the inhibitory receptor NKG2A expressed by CD8 and NK cells. NKG2A was increased after anti-MICA/B treatment and, accordingly, combination of anti-MICA/B and anti-NKG2A was synergistic. These observations were ultimately confirmed in a clinical relevant model of coculture between CRC patients-derived spheroids and autologous tumor-infiltrating lymphocytes. Conclusions Altogether, we show that tumor spheroids represent a relevant tool to study tumor-lymphocyte interactions on human tissues and revealed the antitumor potential of immunomodulatory antibodies targeting MICA/B and NKG2A.

25 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
ACAlexis J. Combes
Alexis J. Combes
TCTristan Courau
Tristan Courau
NKNicholas F. Kuhn
Nicholas F. Kuhn
KHKenneth H. Hu
Kenneth H. Hu
ARArja Ray
Arja Ray
MKMatthew F. Krummel
Matthew F. Krummel

27 December 2021 in Cell
Verified
Journal Article
Closed access
ACAlexis J. Combes
Alexis J. Combes
BSBushra Samad
Bushra Samad
JTJessica Tsui
Jessica Tsui
NCNayvin W. Chew
Nayvin W. Chew
PYPeter Yan
Peter Yan
MKMatthew F. Krummel
Matthew F. Krummel

16 June 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
TCTristan Courau
Tristan Courau
DNDjamel Nehar-Belaid
Djamel Nehar-Belaid
LFLaura Florez
Laura Florez
BLBéatrice Levacher
Béatrice Levacher
TVThomas Vazquez
Thomas Vazquez
DKDavid Klatzmann
David Klatzmann
Tregs imprint an early immunotolerant tumor environment that prevents effective antitumor immune responses. Using transcriptomics of tumor tissues, we identified early upregulation of VEGF and TGF-β pathways compatible with tolerance imprinting. Silencing of VEGF or TGF-β in tumor cells induced early and pleiotropic modulation of immune-related transcriptome signatures in tumor tissues. These were surprisingly similar for both silenced tumors and related to common downstream effects on Tregs. Silencing of VEGF or TGF-β resulted in dramatically delayed tumor growth, associated with decreased Tregs and myeloid-derived suppressor cells and increased effector T cell activation in tumor infiltrates. Strikingly, co-silencing of TGF-β and VEGF led to a substantial spontaneous tumor eradication rate and the combination of their respective inhibitory drugs was synergistic. VEGF and/or TGF-β silencing also restored tumor sensitivity to tumor-specific cell therapies and markedly improved the efficacy of anti–PD-1/anti–CTLA-4 treatment. Thus, TGF-β and VEGF cooperatively control the tolerant environment of tumors and are targets for improved cancer immunotherapies.

1 September 2013 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
TCTing Chen
Ting Chen
GDGuillaume Darrasse-Jeze
Guillaume Darrasse-Jeze
ABAnne-Sophie Bergot
Anne-Sophie Bergot
TCTristan Courau
Tristan Courau
GCGuillaume Churlaud
Guillaume Churlaud
DKDavid Klatzmann
David Klatzmann
Regulatory T cells (Tregs) play crucial roles in both fetal and tumor development. We recently showed that immunosurveillance by pre-existing CD44highCD62Llow activated/memory Tregs (amTregs) specific for self-Ags protects emergent tumor cells in mice. This Treg response of a memory type is more rapid than and dominates the antitumor response of tumor-specific effector T cells. In this study, we report striking similarities between the early Treg responses to embryo and tumor implantation. Tregs are rapidly recruited to uterus-draining lymph nodes and activated in the first days after embryo implantation in both syngeneic and allogeneic matings; express the markers of the amTreg subset; and are at least in part self-Ag specific, as seen in tumor emergence. Unlike in the tumor emergence setting, however, for which preimmunization against tumor Ags is sufficient for complete tumor eradication even in the presence of Tregs, Treg depletion is additionally required for high frequencies of fetus loss after preimmunization against paternal tissue Ags. Thus, amTregs play a major role in protecting embryos in both naive and preimmune settings. This role and the ensuing therapeutic potential are further highlighted by showing that Treg stimulation, directly by low-dose IL-2 or indirectly by Fms-related tyrosine kinase 3 ligand, led to normal pregnancy rates in a spontaneous abortion-prone model.

27 November 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
ARArja Ray
Arja Ray
KHKenneth H. Hu
Kenneth H. Hu
KKKelly Kersten
Kelly Kersten
TCTristan Courau
Tristan Courau
NKNicholas F. Kuhn
Nicholas F. Kuhn
MKMatthew F. Krummel
Matthew F. Krummel
CD206 is a common marker of a putative immunosuppressive “M2” state in tumor-associated macrophages (TAMs). We made a novel conditional CD206 (Mrc1) knock-in mouse to specifically visualize and/or deplete CD206+ TAMs. Early depletion of CD206+ macrophages and monocytes (Mono/Macs) led to the indirect loss of conventional type I dendritic cells (cDC1), CD8 T cells, and NK cells in tumors. CD206+ TAMs robustly expressed CXCL9, contrasting with stress-responsive Spp1-expressing TAMs and immature monocytes, which became prominent with early depletion. CD206+ TAMs differentially attracted activated CD8 T cells, and the NK and CD8 T cells in CD206-depleted tumors were deficient in Cxcr3 and cDC1-supportive Xcl1 and Flt3l expressions. Disrupting this key antitumor axis decreased tumor control by antigen-specific T cells in mice. In human cancers, a CD206Replete, but not a CD206Depleted Mono/Mac gene signature correlated robustly with CD8 T cell, cDC1, and NK signatures and was associated with better survival. These findings negate the unqualified classification of CD206+ “M2-like” macrophages as immunosuppressive.